<DOC>
	<DOCNO>NCT00003499</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally-occurring substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study well antineoplaston therapy work treat patient low-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Patients With Low-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety possible effectiveness antineoplastons A10 AS2-1 patient serious immediately life-threatening low grade non-Hodgkin 's lymphoma . - Describe response , tolerance , side effect regimen patient . OUTLINE : This open label study . Patients receive gradually escalate dos intravenous antineoplaston A10 antineoplaston AS2-1 6 time per day maximum tolerate dose reach . Treatment continue least 12 month absence disease progression unacceptable toxicity . After 12 month , patient respond stable disease may continue treatment . Tumors measure every 8 week first 6 month , every 3 month first 2 year , every 6 month year 3 4 , yearly year 5 6 . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage II , III , IV low grade nonHodgkin 's lymphoma unlikely respond exist therapy establish therapy exist NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC great 2,000/mm^3 Platelet count great 20,000/mm^3 Hepatic : Bilirubin normal Renal : Creatinine normal No history renal condition contraindicate high dosage sodium Cardiovascular : No hypertension No history congestive heart failure No history cardiovascular condition contraindicate high dosage sodium Other : Not pregnant nursing Fertile patient must use effective contraception 4 week study No serious active infection PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since immunotherapy recover No concurrent immunomodulating agent ( e.g. , interferon , interleukin2 ) Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover Endocrine therapy : At least 4 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : At least 8 week since prior radiotherapy recover Surgery : Not specify Other : No prior antineoplaston therapy No concurrent antineoplastic agent No concurrent antibiotic , antifungal , antiviral</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
</DOC>